Development of Deferoxamine-Functionalized Cyclodextrin Polymer for Targeted Iron Chelation

Area of Science:

• Biomaterials Science
• Medicinal Chemistry
• Nanotechnology

Background:

• Polymeric systems offer improved pharmacokinetics and reduced side effects compared to small-molecule drugs.
• Deferoxamine is a critical iron chelator for treating iron overload but can exhibit significant toxicity.
• Targeted delivery of chelators can enhance efficacy and minimize adverse effects.

Purpose of the Study:

• To synthesize and characterize a novel deferoxamine-based polymeric conjugate for enhanced iron chelation therapy.
• To evaluate the cytotoxicity and iron-binding capacity of the new conjugate compared to free deferoxamine.
• To explore the potential of cyclodextrin-based polymers for improved drug delivery in iron dyshomeostasis.

Main Methods:

• Synthesis of a cross-linked β-cyclodextrin polymer functionalized with deferoxamine.
• Characterization of the deferoxamine polymeric conjugate's complexing capacity.
• In vitro cytotoxicity assessment across multiple cancer cell lines (SHSY5Y, MDA-MB-231, A2780, A549).

Main Results:

• The deferoxamine polymeric conjugate exhibited an iron-binding capacity equivalent to free deferoxamine.
• Significantly lower cytotoxicity was observed for the conjugate across all tested cancer cell lines compared to deferoxamine alone.
• The conjugation effectively reduced the inherent toxicity of deferoxamine without compromising its chelating function.

Conclusions:

• Deferoxamine-based cyclodextrin conjugates represent a promising strategy for developing safer and more effective iron chelators.
• This approach offers a novel therapeutic avenue for managing iron overload disorders and related pathologies.
• The study highlights the potential of functionalized polymeric systems in drug delivery and toxicity mitigation.